Environment

New Xconomy Podcast & Special Report Feature Boston Biophama Leaders on Digital Health

22 days ago   |   By Xconomy

Miss Xconomy's Xcelerating Life Sciences Boston: Biopharma's Future in Digital Health event or want to revisit the insightful content? Our new podcast and special report package the highlights for you. Listen to the podcast or download the report today. The podcast includes expert panels on: The convergence of data supporting emerging therapies Navigating approaches in a complex regulatory environment Managing the patient in the world of personalized medicine The special report articles include: How Crisis and Opportunity Are Pushing Digital Health Front and Center Digital Therapies...
Read more ...

 


Search by Tags

   Environment      Science      BioPharma      Biopharma      Medicine      Health      Life Sciences      Therapies      Boston      Boston blog main      Boston top stories      National      National blog main      National top stories      Artificial Intelligence      Biotech      Digital Health      Exome      Life Science      Podcast      Special Report      XconBOS  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It's a particularly pronounced problem for therapies employing... Read more ...

Interpreting the Human Genome's Instruction Manual

Interpreting the Human Genome's Instruction Manual

An artistic representation of gene regulating elements, which allow cells with the same genetic code to differentiate into many different tissues and play many varied roles in... Read more ...

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that... Read more ...

As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients... Read more ...

Kristin Persson Named Director of Berkeley Lab's Molecular Foundry

Kristin Persson Named Director of Berkeley Lab's Molecular Foundry

Kristin Persson Kristin Persson, a senior faculty scientist in the Energy Storage & Distributed Resources Division within the Energy Technologies Area at Lawrence Berkeley... Read more ...

Geothermal Brines Could Propel California's Green Economy

Geothermal Brines Could Propel California's Green Economy

Thermal mud pots at Controlled Thermal Resources' project site at the Salton Sea. Deep beneath the surface of the Salton Sea, a shallow lake in California's Imperial County... Read more ...

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs... Read more ...

CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage

CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage

CymaBay Therapeutics' investigational drug seladelpar succeeded in a late-stage trial in patients with primary biliary cholangitis , producing results that suggest it could... Read more ...

Conservation machine learning

Read more ...

Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment...

Technology, expertise from UK's Mucokinetica to accelerate repurposing of generic remedy nafamostat for COVID-19 oral, inhalation therapy SAN DIEGO, Aug. 6, 2020 /PRNewswire... Read more ...